Cited by 1,134Melanoma and MAPK PathwaysLung Cancer Treatments and MutationsCancer Mechanisms and Therapy

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Open access

Wilson, Timothy R., Fridlyand, Jane, Yan, Yibing, Penuel, Elicia, Burton, Luciana, Chan, Emily, Peng, Jing, Lin, Eva, Wang, Yulei, Sosman, Jeff, Ribas, Antoni, Li, Jiang, Moffat, John, Sutherlin, Daniel P., Koeppen, Hartmut, Merchant, Mark, Neve, Richard, Settleman, Jeff·2012·Nature

DOI 10.1038/nature11249PMC PMC3724525

Open this paper in CoChat — free account

Abstract

Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy. However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance. The identification of resistance mechanisms has revealed a recurrent theme—the engagement of survival signals redundant to those transduced by the targeted kinase. Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors—most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK). Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-'addicted' human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature11249

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1477 · Cited by 1,817
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Self-citation
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

Flagged first, then by citations

Show all 29 references

Sorted by citations

Items 701–800 of 1,000

Synthesis, characterization and in vitro evaluation of novel vitamin D3 nanoparticles as a versatile platform for drug delivery in cancer therapy
Patil, S., Gawali, S., Patil, S., & Basu, S. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb21176b · Cited by 22
It's Getting Hot in Here: Targeting Cancer Stem-like Cells with Hyperthermia.
Huang, H., Yu, K., Mohammadi, A. M., Karanthanasis, E., Godley, A. R., & Ma, J. S. Y. (2017) · PubMed · Cited by 20
Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma
Wang, J., Mirzapoiazova, T., Tan, Y. C., Pang, K. M., Pozhitkov, A. E., Wang, Y., Wang, Y., Mambetsariev, B., Wang, W., Nasser, M. W., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1472193 · Cited by 20
NK92-CD16 cells are cytotoxic to non-small cell lung cancer cell lines that have acquired resistance to tyrosine kinase inhibitors
Park, H.-R., Ahn, Y., Kim, T. M., Kim, S., Kim, S., LEE, Y. S., KIM, M., Keam, B., Kim, D.-W., & Heo, D. S. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.03.312 · Cited by 20
Cancer-Associated Fibroblasts Induce Proliferation and Therapeutic Resistance to Everolimus in Neuroendocrine Tumors through STAT3 Activation
Amin, T., Viol, F., Krause, J., Fahl, M., Eggers, C., Awwad, F., Schmidt, B., Benten, D., Ungefroren, H., Fraune, C., et al. (2022) · Neuroendocrinology · doi:10.1159/000528539 · Cited by 20
A Systems-Level Interrogation Identifies Regulators of Drosophila Blood Cell Number and Survival
Sopko, R., Lin, Y. B., Makhijani, K., Alexander, B., Perrimon, N., & Brückner, K. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005056 · Cited by 19
FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice
Zhao, Q., Parris, A. B., Howard, E. W., Zhao, M., Ma, Z., Guo, Z., Xing, Y., & Yang, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-11751-7 · Cited by 20
Intratumoral heterogeneity and consequences for targeted therapies
Turtoï, A., Blomme, A., & Castronovo, V. (2015) · Bulletin du Cancer · doi:10.1016/j.bulcan.2014.12.006 · Cited by 19
Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer
Creedon, H., Byron, A., Main, J., Hayward, L., Klinowska, T. C. M., & Brunton, V. G. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140109 · Cited by 19
An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo
Tomoshige, K., Guo, M., Tsuchiya, T., Fukazawa, T., Fink-Baldauf, I. M., Stuart, W. D., Naomoto, Y., Nagayasu, T., & Maeda, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0240-1 · Cited by 20
Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management
Chakrabarti, S., Finnes, H. D., & Mahipal, A. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2039118 · Cited by 19
Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and Perspectives
Olbryt, M. (2022) · Cancers · doi:10.3390/cancers14092315 · Cited by 19
Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells
Yi, Y. W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043704 · Cited by 20
Met receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions
Pomerleau, V., Landry, M., Bernier, J., Vachon, P. H., & Saucier, C. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-240 · Cited by 19
Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance
Truitt, L., Hutchinson, C., DeCoteau, J. F., & Geyer, C. R. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.37 · Cited by 19
Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors
Lezcano, C. M., Lee, C., Larson, A. R., Menzies, A. M., Kefford, R. F., Thompson, J. F., Mihm, M. C., Ogino, S., Long, G. V., Scolyer, R. A., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.226 · Cited by 19
Recent Progress on Inhibitors of the Type II Transmembrane Serine proteases, hepsin, Matriptase and matriptase-2
Damalanka, V. C., & Janetka, J. W. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0446 · Cited by 20
Integrin β8 facilitates tumor growth and drug resistance through a Y‐box binding protein 1‐dependent signaling pathway in bladder cancer
Liu, S., Chen, L., Zhao, H., Li, Q., Hu, R., & Wang, H. (2020) · Cancer Science · doi:10.1111/cas.14439 · Cited by 19
Multiple roles of extracellular fibroblast growth factors in lung cancer cells
Suzuki, T., Yasuda, H., FUNAISHI, K., Arai, D., Ishioka, K., Ohgino, K., Tani, T., Hamamoto, J., Ohashi, A., Naoki, K., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2718 · Cited by 19
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
Ghasemi, R., Rapposelli, I. G., Capone, E., Rossi, C., Lattanzio, R., Piantelli, M., Sala, G., & Iacobelli, S. (2014) · Oncogenesis · doi:10.1038/oncsis.2014.31 · Cited by 19
Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment
Ng, Y., Lee, J.-Y. L., Supko, K. M., Khan, A. U., Torres, S. M., Berwick, M., Ho, J., Kirkwood, J. M., Siegfried, J. M., & Stabile, L. P. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000060 · Cited by 19
Initiation of a formalized precision medicine program in gynecologic oncology
Gunderson, C. C., Rowland, M. R., Wright, D., Andrade, K., Mannel, R. S., McMeekin, D. S., & Moore, K. N. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.02.024 · Cited by 19
BRAF Targeting Across Solid Tumors: Molecular Aspects and Clinical Applications
Mechahougui, H., Gutmans, J., Gouasmi, R., Smekens, L., & Friedlaender, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083757 · Cited by 19
Effect of cancer-associated fibroblasts on radiosensitivity of cancer cells
Ji, X., Zhu, X., & Lu, X. (2017) · Future Oncology · doi:10.2217/fon-2017-0054 · Cited by 18
Heparan Sulfate Synthesized by Ext1 Regulates Receptor Tyrosine Kinase Signaling and Promotes Resistance to EGFR Inhibitors in GBM
Ohkawa, Y., Wade, A., Lindberg, O. R., Chen, K. Y., Tran, V. M., Brown, S. J., Kumar, A., Kalita, M., James, C. D., & Phillips, J. J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0420 · Cited by 19
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer
Centuori, S. M., & Bauman, J. E. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000619 · Cited by 18
Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Malone, C. F., Kim, M., Alexe, G., Engel, K. L., Forman, A. B., Robichaud, A. L., Conway, A. S., Goodale, A. B., Meyer, A., Khalid, D., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4309 · Cited by 19
Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic
Fabi, A., Mottolese, M., & Segatto, O. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1169-7 · Cited by 18
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas
Roller, D. G., Capaldo, B. J., Bekiranov, S., Mackey, A. J., Conaway, M. R., Petricoin, E. F., Gioeli, D. G., & Weber, M. J. (2015) · Oncotarget · doi:10.18632/oncotarget.6548 · Cited by 18
Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma
Hügel, R., Muendlein, A., Volbeding, L., Drexel, H., Richtig, E., Wehkamp, U., Painsi, C., Lange‐Asschenfeldt, B., Hauschild, A., & Egberts, F. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000269 · Cited by 18
Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells
Oppermann, S., Lam, A. J., Tung, S., Shi, Y., McCaw, L., Wang, G., Ylanko, J., Leber, B. F., Andrews, D. W., & Spaner, D. (2016) · Oncotarget · doi:10.18632/oncotarget.11618 · Cited by 18
Computational algorithms for in silico profiling of activating mutations in cancer
Jordan, E. J., Patil, K., Suresh, K., Park, J. H., Mossé, Y. P., Lemmon, M. A., & Radhakrishnan, R. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03097-2 · Cited by 18
Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors
Schultink, A. H. M. D. V., Bol, K., Doornbos, R. P., Murat, A., Wasserman, E., Dorlo, T. P. C., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00858-2 · Cited by 18
Assessing Current Therapeutic Approaches to Decode Potential Resistance Mechanisms in Glioblastomas
Sze, C., Su, W.-P., Chiang, M., Lu, C.-Y., Chen, Y., & Chang, N. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00059 · Cited by 20
Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells
Kim, J., Lee, J., Kim, C., Choi, J., & Kim, A. (2015) · Tumor Biology · doi:10.1007/s13277-015-4440-9 · Cited by 21
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A
Bergamo, A., Pelillo, C., Chambery, A., & Sava, G. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.11.031 · Cited by 18
CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
Werr, L., Plenker, D., Dammert, M. A., Lorenz, C., Brägelmann, J., Tumbrink, H. L., Klein, S., Schmitt, A., Büttner, R., ten Persigehl, T., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0820 · Cited by 20
Registered report: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Blum, D. L., LaBarge, S. A., & Reproducibility Project: Cancer Biology (2014) · eLife · doi:10.7554/elife.04034 · Cited by 17
Resistance to Oncolytic Myxoma Virus Therapy in Nf1−/−/Trp53−/− Syngeneic Mouse Glioma Models Is Independent of Anti-Viral Type-I Interferon
Zemp, F. J., McKenzie, B., Lun, X. Q., Maxwell, L., Reilly, K. M., McFadden, G., Yong, V. W., & Forsyth, P. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065801 · Cited by 17
In vivo detection of drug-induced apoptosis in tumors using Raman spectroscopy
Jonas, O. H., Kang, J. W., Singh, S. P., Lammers, A., Nguyen, F. T., Dasari, R. R., So, P. T. C., Langer, R., & Cima, M. J. (2018) · The Analyst · doi:10.1039/c8an00913a · Cited by 17
Gene-Specific Intron Retention Serves as Molecular Signature that Distinguishes Melanoma from Non-Melanoma Cancer Cells in Greek Patients
Giannopoulou, A. F., Konstantakou, E. G., Velentzas, A. D., Avgeris, S. N., Avgeris, M., Papandreou, N. C., Zoi, I., Filippa, V., Katarachia, S. A., Lampidonis, A. D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040937 · Cited by 16
Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma
Khaledian, B., Taguchi, A., Shin‐ya, K., Kondo‐Ida, L., Kagaya, N., Suzuki, M., Kajino, T., Yamaguchi, T., Shimada, Y., & Takahashi, T. (2020) · Cancer Science · doi:10.1111/cas.14786 · Cited by 17
MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation
Chen, T. T., Filvaroff, E. H., Peng, J., Marsters, S. A., Jubb, A. M., Koeppen, H., Merchant, M. A., & Ashkenazi, A. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.03.021 · Cited by 17
Molecular Pathways: Multimodal Cancer-Killing Mechanisms Employed by Oncolytic Vesiculoviruses
Mahoney, D. J., & Stojdl, D. F. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3149 · Cited by 17
WINDOW consortium: A path towards increased therapy efficacy against glioblastoma
Abdul, K., Houweling, M., Svensson, F., Narayan, R. S., Cornelissen, F. M. G., Küçükosmanoğlu, A., Metzakopian, E., Watts, C., Bailey, D. S., Würdinger, T., et al. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.10.001 · Cited by 16
Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
Geneste, A., Duong, M. N., Molina, L., Conilh, L., Beaumel, S., Cleret, A., Chettab, K., Lachat, M., Jordheim, L. P., Matera, E., et al. (2020) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-020-00436-z · Cited by 17
Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors
Peron, M., Lovisa, F., Poli, E., Basso, G., & Bonvini, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0132330 · Cited by 16
LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance
Billing, O., Holmgren, Y., Nosek, D., Hedman, H., & Hemmingsson, O. (2021) · Oncogene · doi:10.1038/s41388-021-01808-3 · Cited by 16
Mannose Phosphate Isomerase Regulates Fibroblast Growth Factor Receptor Family Signaling and Glioma Radiosensitivity
Cazet, A., Charest, J., Bennett, D. C., Sambrooks, C. L., & Contessa, J. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0110345 · Cited by 17
Developing melanoma therapeutics: overview and update
Korman, J. B., & Fisher, D. E. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1210 · Cited by 16
8thAnnual European Antibody Congress 2012
Beck, A., Carter, P. J., Gerber, H., Lugovskoy, A. A., Wurch, T., Junutula, J. R., Kontermann, R. E., & Mabry, R. (2013) · mAbs · doi:10.4161/mabs.24105 · Cited by 16
Synthesis and biological evaluation of 2,4-disubstituted thiazole amide derivatives as anticancer agent
Zhang, Z., Wu, H., Deng, S.-N., Chai, R.-X., Mwenda, M. C., Peng, Y., Cai, D. Q., & Chen, Y. (2018) · Chemical Papers · doi:10.1007/s11696-018-0587-3 · Cited by 16
Applications of personalised signalling network models in precision oncology
Hastings, J. F., O’Donnell, Y. E. I., Fey, D., & Croucher, D. R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107555 · Cited by 18
Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling
Campbell, M. R., Ruiz-Sáenz, A., Zhang, Y., Peterson, E., Steri, V., Oeffinger, J., Sampang, M., Jura, N., & Moasser, M. M. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110285 · Cited by 16
Prostate derived Ets transcription factor and Carcinoembryonic antigen related cell adhesion molecule 6 constitute a highly active oncogenic axis in breast cancer
Mukhopadhyay, A., Khoury, T., Stein, L. C., Shrikant, P. A., & Sood, A. K. (2013) · Oncotarget · doi:10.18632/oncotarget.934 · Cited by 16
Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine
Warthaka, M., Adelmann, C. H., Kaoud, T. S., Edupuganti, R., Yan, C., Johnson, W. H., Ferguson, S. B., Tavares, C. D. J., Pence, L. J., Anslyn, E. V., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500198b · Cited by 15
Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung.
Méndez, P., & Ramírez, J. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.05 · Cited by 16
EMT Twists the Road to PI3K
Niederst, M. J., & Benes, C. H. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-1030 · Cited by 16
Association of AMPK subunit gene polymorphisms with growth, feed intake, and feed efficiency in meat-type chickens
Jin, S., Moujahid, E. M. E., Duan, Z., Zheng, J., Qu, L., Xu, G., Yang, N., & Chen, S. (2016) · Poultry Science · doi:10.3382/ps/pew081 · Cited by 17
Deciphering fibroblast-induced drug resistance in non-small cell lung carcinoma through patient-derived organoids in agarose microwells
Luan, Q., Pulido, I., Isagirre, A., Carretero, J., Zhou, J., Shimamura, T., & Papautsky, I. (2024) · Lab on a Chip · doi:10.1039/d3lc01044a · Cited by 17
Integrated network analyses for functional genomic studies in cancer
Wilson, J. L., Hemann, M. T., Fraenkel, E., & Lauffenburger, D. A. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.06.004 · Cited by 15
Impact of MET expression on outcome in BRAF V600E/K advanced melanoma
Jubb, A. M., Ribas, A., Sosman, J. A., McArthur, G. A., Yan, Y., Rost, S., Zhao, S. S., & Koeppen, H. (2013) · Histopathology · doi:10.1111/his.12169 · Cited by 15
Converting Biology into Clinical Benefit: Lessons Learned from BRAF Inhibitors
McQuade, J. L., & Davies, M. A. (2015) · Melanoma Management · doi:10.2217/mmt.15.18 · Cited by 15
Receptor Tyrosine Kinase Phosphorylation Pattern–Based Multidrug Combination Is an Effective Approach for Personalized Cancer Treatment
Sun, X., Song, Q., He, L., Yan, L., Liu, J., Zhang, Q., & Yu, Q. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0735 · Cited by 15
Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine
Pool, M., de Boer, H. R., Hooge, M. N. L., van Vugt, M. A. T. M., & de Vries, E. G. E. (2017) · Theranostics · doi:10.7150/thno.17934 · Cited by 15
Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study
REPOSIT study group, van der Hiel, B., Haanen, J. B. A. G., Stokkel, M. P. M., Peeper, D. S., Jiménez, C. R., Beijnen, J. H., van de Wiel, B. A., Boellaard, R., & van den Eertwegh, A. J. M. (2017) · BMC Cancer · doi:10.1186/s12885-017-3626-5 · Cited by 15
JIB‑04 induces cell apoptosis via activation of the p53/Bcl‑2/caspase pathway in MHCC97H and HepG2 cells
Liao, W., Liu, J., Liu, B., Huang, X., Yin, Y., Cai, D., Li, M., & Zhu, R. (2018) · Oncology Reports · doi:10.3892/or.2018.6737 · Cited by 16
Basic fibroblast growth factor promotes doxorubicin resistance in chondrosarcoma cells by affecting XRCC5 expression
Hsieh, M., Huang, C., Lin, C., Tang, C., Lin, C., Lee, I., Huang, H., & Chen, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23153 · Cited by 15
Engineering of HN3 increases the tumor targeting specificity of exosomes and upgrade the anti-tumor effect of sorafenib on HuH-7 cells
He, C., Ali, D. J., Li, Y., Zhu, Y., Sun, B., & Xiao, Z. (2020) · PeerJ · doi:10.7717/peerj.9524 · Cited by 15
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression
Damalanka, V. C., Voss, J. J. L. P., Mahoney, M. W., Primeau, T. M., Li, S., Klampfer, L., & Janetka, J. W. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01671 · Cited by 15
High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients
van den Hurk, K., Bálint, B., Toomey, S., O’Leary, P. C., Unwin, L., Sheahan, K. D., McDermott, E. W. M., Murphy, I., van den Oord, J. J., Rafferty, M., et al. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000149 · Cited by 15
Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition
Edgar, K. A., Crocker, L., Cheng, E., Wagle, M.-C., Wongchenko, M. J., Yan, Y., Wilson, T. R., Dompe, N., Neve, R. M., Belvin, M. P., et al. (2014) · Genes & Cancer · doi:10.18632/genesandcancer.10 · Cited by 15
Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3Kα: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives
Yin, Y., Wu, X., Han, H., Sha, S., Wang, S., Qiao, F., Lu, A., Lv, P., & Zhu, H. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob01589d · Cited by 15
Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007 – present)
Sacco, E., Spinelli, M., & Vanoni, M. (2012) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2012.728586 · Cited by 16
Down-Regulation of DDR1 Induces Apoptosis and Inhibits EMT through Phosphorylation of Pyk2/MKK7 in DU-145 and Lncap-FGC Prostate Cancer Cell Lines
Azizi, R., Fallahian, F., Aghaei, M., & Salemi, Z. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200410075558 · Cited by 15
Human blood serum can donor-specifically antagonize effects of EGFR-targeted drugs on squamous carcinoma cell growth
Kamashev, D., Sorokin, M., Kochergina, I., Drobyshev, A., Vladimirova, U., Zolotovskaia, M., Vorotnikov, I. K., Shaban, N., Raevskiy, M., Kuzmin, D., et al. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e06394 · Cited by 15
Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
Tan, A. C., Teh, Y. L., Lai, G. G. Y., & Tan, D. S.-W. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1604228 · Cited by 15
Cardiac Safety of Kinase Inhibitors – Improving Understanding and Prediction of Liabilities in Drug Discovery Using Human Stem Cell-Derived Models
Ziegler, R., Häusermann, F., Kirchner, S., & Polonchuk, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.639824 · Cited by 14
RICTOR Affects Melanoma Tumorigenesis and Its Resistance to Targeted Therapy
Jebali, A., Battistella, M., Lebbé, C., & Dumaz, N. (2021) · Biomedicines · doi:10.3390/biomedicines9101498 · Cited by 14
Bone Marrow Adipocytes Contribute to Tumor Microenvironment-Driven Chemoresistance via Sequestration of Doxorubicin
Kwak, J., & Lee, J. (2023) · Cancers · doi:10.3390/cancers15102737 · Cited by 14
Human Blood Serum Can Diminish EGFR-Targeted Inhibition of Squamous Carcinoma Cell Growth through Reactivation of MAPK and EGFR Pathways
Kamashev, D., Shaban, N., Lebedev, T., Prassolov, V., Suntsova, M., Raevskiy, M., Gaifullin, N., Sekacheva, M., Garazha, A., Poddubskaya, E., et al. (2023) · Cells · doi:10.3390/cells12162022 · Cited by 14
Akt isoforms differentially provide for chemoresistance in prostate cancer
Ma, B., Shao, H., Jiang, X., Wang, Z., Wu, C., Whaley, D., & Wells, A. H. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0747 · Cited by 14
Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids
Gong, K., Guo, G., Beckley, N. A., Yang, X., Zhang, Y., Gerber, D. E., Minna, J. D., Burma, S., Zhao, D., Akbay, E. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27276-7 · Cited by 15
MicroRNA-631 Resensitizes Doxorubicin-Resistant Chondrosarcoma Cells by Targeting Apelin
Chen, J., Shih, H.-C., Lin, C., Guo, J., Huang, C., Huang, H., Chong, Z.-Y., & Tang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010839 · Cited by 14
Thyrocyte‐specific deletion of insulin and IGF‐1 receptors induces papillary thyroid carcinoma‐like lesions through EGFR pathway activation
Ock, S., Ahn, J., Lee, S. H., Kim, H. M., Kang, H., Kim, Y. K., Kook, H., Park, W. J., Kim, S., Kimura, S., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31779 · Cited by 14
Secreted amphiregulin promotes vincristine resistance in oral squamous cell carcinoma
Hsieh, M., Chen, Y., Lee, I., Huang, C., Ku, Y., & Chen, J. (2019) · International Journal of Oncology · doi:10.3892/ijo.2019.4866 · Cited by 14
Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment
Pardella, E., Pranzini, E., Leo, A., Taddei, M. L., Paoli, P., & Raugei, G. (2020) · Cancers · doi:10.3390/cancers12102799 · Cited by 14
Microvesicles mediate sorafenib resistance in liver cancer cells through attenuating p53 and enhancing FOXM1 expression
Ali, D. J., He, C., Xu, H., Kumaravel, S., Sun, B., Zhou, Y., Liu, R., & Xiao, Z. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119149 · Cited by 14
The broad‐spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF ‐mutant melanoma cells in combination with other signaling pathway inhibitors
Langdon, C. G., Held, M. A., Platt, J. T., Meeth, K. M., Iyidogan, P., Mamillapalli, R., Koo, A. B., Klein, M., Liu, Z. Z., Bosenberg, M., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12376 · Cited by 13
The epigenome and the many facets of cancer drug tolerance
Moore, P. C., Henderson, K. W., & Classon, M. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2022.12.002 · Cited by 14
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF
Kondo, N., Utsumi, T., Shimizu, Y., Takemoto, A., Oh‐hara, T., Uchibori, K., Subat-Motoshi, S., Ninomiya, H., Takeuchi, K., Nishio, M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.173688 · Cited by 15
The MET Oncogene: Thirty Years of Insights into Molecular Mechanisms Driving Malignancy
Crepaldi, T., Gallo, S., & Comoglio, P. M. (2024) · Pharmaceuticals · doi:10.3390/ph17040448 · Cited by 13
TGF ‐β1 and TNF ‐α differentially regulate T wist1 mediated resistance towards BRAF / MEK inhibition in melanoma
Menon, D. R., Wels, C., Rad, E. B., Joshi, S., Knausz, H., Lade‐Keller, J., Brandner, J. M., & Schaider, H. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12139 · Cited by 14
Combinatorial Therapy Using Dovitinib and ICI182.780 (Fulvestrant) Blocks Tumoral Activity of Endometrial Cancer Cells
Eritja, N., Domingo, M., Dosil, M. A., Mirantes, C., Santacana, M., Valls, J., Llombart‐Cussac, A., Matías‐Guiu, X., & Dolcet, X. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0794 · Cited by 13
Hyaluronic acid cloaked oleic acid nanoparticles inhibit MAPK signaling with sub-cellular DNA damage in colon cancer cells
Palvai, S., Kuman, M. M., & Basu, S. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00656j · Cited by 13
Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities
Grit, J. L., Pridgeon, M., Essenburg, C. J., Wolfrum, E., Madaj, Z., Turner, L., Wulfkuhle, J. D., Petricoin, E. F., Graveel, C. R., & Steensma, M. R. (2020) · Genes · doi:10.3390/genes11030331 · Cited by 13
Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
Schulz, A., Raetz, J., Karitzky, P. C., Dinter, L., Tietze, J. K., Kolbe, I., Käubler, T., Renner, B., Beissert, S., Meier, F. E., et al. (2022) · Cancers · doi:10.3390/cancers14194930 · Cited by 15
Circulating hepatocyte growth factor is correlated with resistance to cetuximab in metastatic colorectal cancer.
Yonesaka, K., Satoh, T., Ueda, S., Yoshida, T., Takeda, M., Shimizu, T., Okamoto, I., Nishio, K., Tamura, T., & Nakagawa, K. (2015) · PubMed · Cited by 13
Reading between the lines; understanding drug response in the post genomic era
Alifrangis, C., & McDermott, U. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.014 · Cited by 13
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities
Sharan, S., & Woo, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00033 · Cited by 13

Authors: Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D. P., Koeppen, H., Merchant, M., Neve, R., & Settleman, J.
Affiliations: Genentech (US)
Vanderbilt University Medical Center (US)
University of California, Los Angeles (US)
Corresponding author: Settleman, Jeff
ORCID: Wilson, Timothy R.
Penuel, Elicia
Chan, Emily
Peng, Jing
Lin, Eva
Wang, Yulei
Ribas, Antoni
Koeppen, Hartmut
Merchant, Mark
Neve, Richard
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-07
Volume: 487
Issue: 7408
Pages: 505-509
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature11249
PMC: PMC3724525
OpenAlex: W1999025555
Cited by: 1,134
References: 29
Citations by year: 2026: 23 · 2025: 16 · 2024: 31 · 2023: 46 · 2022: 47 · 2021: 51 · 2020: 65 · 2019: 70 · 2018: 85 · 2017: 87 · 2016: 125 · 2015: 137 · 2014: 166 · 2013: 150 · 2012: 34
FWCI: 62.91
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: National Cancer Institute (K24CA097588)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: drug resistance, kinase inhibitors, receptor tyrosine kinase, growth factors, hepatocyte growth factor, BRAF inhibitors, vemurafenib, melanoma, tumor microenvironment, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, combination therapy
MeSH terms: Lapatinib, Vemurafenib, Antineoplastic Agents, Breast Neoplasms, Cell Survival, Female, Humans, Indoles, Ligands, Melanoma, Quinazolines, Sulfonamides, Signal Transduction, Hepatocyte Growth Factor, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks